One option that may affect how well patients tolerate their statin treatment is the COQ2 gene, which codes for the polyprenyltransferase (coenzyme Q2) enzyme. This enzyme aids in the production of coenzyme Q10 (CoQ10), whose depletion is triggered by statin medication and is regarded to be a contributing factor in the development of statin-related muscle symptoms. Therefore, statin-induced myopathy susceptibility may be explained by COQ2 gene polymorphisms. Myopathy is a prominent side effect of statins that leads to intolerance and ultimately the drug's discontinuation. The Imam Al-Hussein Medical City in Kerbala hosted the cross-sectional observational study. The trial's participants included 150 individuals who were atorvastatin users in total. A 40 mg atorvastatin tablet was administered once daily to all of the trial's participants, whose ages ranged from 30 to 65. Coenzyme Q10, lipid profile (cholesterol, triglyceride, low-density lipoprotein, and high-density lipoprotein), renal function test (creatinine), creatinine kinase, and thyroid stimulating hormone were all measured in blood samples taken from patients who had given informed consent for genetic testing. In this work, COQ2 (A>G) was found using the Amplification Refractory Mutation System Polymerase Chain Reaction (ARMS PCR) (rs6535454). In the Iraqi dyslipidemic patients , there is a significant effect of common polymorphisms (rs6535454) within the COQ2 gene, this poses a risk of developing myopathy associated with the use of atorvastatin.

myopathy, atorvastatin, COQ2 gene, Coenzyme Q10.